Muscimol, thought to be a agonist of γ-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.
|Original language||English (US)|
|Number of pages||4|
|Journal||Archives of General Psychiatry|
|State||Published - May 1979|
ASJC Scopus subject areas
- Arts and Humanities (miscellaneous)
- Psychiatry and Mental health